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Summary Numerous studies have shown that intact cancer cells and cell extracts have the capacity to lyse
erythrocytes in vitro. The transformation of NIH-3T3 fibroblasts by ras oncogenes has recently been demon-
strated to result in tumour cells releasing a haemolytic factor. The purpose of this study has been to purify and
further characterise the soluble tumour haemolytic factor (sTHF) produced by mouse fibroblasts transformed
by T24 human bladder cancer DNA and by the cloned Harvey murine sarcoma viral oncogene. To this end,
transformed fibroblasts were cultivated in serum-free medium. The cell-free supernatant was treated with
ammonium sulphate and the precipitate achieved at 60- 100% saturation was dialysed and applied to a gel
filtration column. A haemolytic factor was eluted with an Mr between 65,000 and 75,000. Zinc chelate and
strong anion exchange column chromatography resulted in greater than 3,000-fold enrichment of sTHF.
SDS-PAGE of sTHF resulted in a single protein band of 66,000 Da. Soluble THF had no immunological
cross-reactivity with known cytokines produced by lymphocytes and macrophages. The pathophysiological
role of sTHF in cancer remains to be determined.
Since the turn of the century, scientists have been searching
for factors, unique to tumour cells, which may be important
in damaging normal cells and tissues. The anaemia of cancer,
a common complication of advanced malignancy, was attri-
buted to the elaboration of a toxin by the tumour (Weil,
1907). Supportive evidence for this hypothesis came from the
demonstration that crude tumour homogenates were able to
lyse red blood cells (Panzacchi, 1902; Micheli & Donati,
1903). Weil (1907) reported that the haemolytic principle of
necrotic tumour extracts was dialysable whereas that of non-
necrotic tumours was not.
Renewed interest in this phenomenon occurred when it
was shown that cancer cells propagated in vitro were able to
lyse erythrocytes (Zucker & Lysik, 1977). In some tumour
cell lines the haemolytic activity was caused by a serine
protease (DiStefano et al., 1982; Steven et al., 1982), but in
most other cell lines tumour-induced haemolysis was a metal
dependent process (Zucker et al., 1985a,b). Subcellular frac-
tionation procedures revealed that the plasma membranes of
cancer cells were considerably enriched in haemolytic activity.
Purification of tumour membrane-bound haemolytic factor
has been hampered by the requirement for detergents to
extract the factor and maintain solubility during purification
(Zucker, unpublished data).
Using transformed cell lines as a model system to analyse
characteristics of cancer cells, Wieman et al. (1986) demon-
strated that the transformation of NIH-3T3 fibroblasts by
the Harvey ras murine sarcoma viral oncogene resulted in the
acquisition of haemolytic activity by the transformed cells. A
haemolytic factor was partially purified from serum-free con-
ditioned media of bladder cancer transformed fibroblasts and
was demonstrated to be a metal dependent, heat-labile pro-
tein of approximately 66,000 Da. This report describes the
further purification and characterisation of this soluble THF
(sTHF) isolated from both viral and human T-24 bladder
cancer-transformed cells.
Materials and methods
Animals and reagents
Wistar rats were used for the preparation of 59Fe-labelled red
blood cells. Chemicals were obtained from Sigma Chemicals.
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Immunological reagents were purchased from Bethesda
Research Labs. Anti-perforin antisera from rabbits hyper-
immunised to rat large granular lymphocyte granules was a
gift from Dr Pierre Henkart (National Institutes of Health,
Bethesda, MD, USA). Anti-tumour necrosis factor was a gift
of Dr Barbara Sherry (Rockefeller University, NY, USA).
Transformed tumour cell lines
The NIH-3T3 cell line was transformed using the calcium
phosphate precipitation method with the cloned viral Harvey
ras oncogene as described by Defeo et al. (1981). NIH-3T3
fibroblasts were transformed with heavy molecular weight
DNA from the T24 bladder cancer cell line, which contains
an activated C-Harvey ras oncogene (a glycine to valine
substitution at amino acid 12) as described by Reddy et al.
(1982). The invasive properties of the T-24 transformed cell
line did not differ from the v-Ha-ras transformed cell line.
The median nude mouse survival after intraperitoneal trans-
plantation of both cell lines was 17 days. Cells were cultured
at 37°C and 5% CO2 in Dulbecco's modified Eagle's medium
plus 10% donor calf serum as previously described (Zucker
et al., 1985b).
Purification of THF
Tumour conditioned medium was harvested after a 2-day
incubation of subconfluent oncogene transformed fibroblasts
in Dulbecco's medium without calf serum. After centrifuga-
tion at 1,500g to remove cells and particulate matter, the
supernatant was treated with solid ammonium sulphate to
achieve a saturation of60%. The precipitate was removed by
centrifugation and additional ammonium sulphate was added
to achieve a final concentration of 100%. Centrifugation
yielded a precipitate which was redissolved, dialysed in
10 mM HEPES buffered (pH 7.2) NaCI (1 M), and applied to
an Ultragel AcA 44 gel filtration column (89 x 1.6 cm; LKB
Instruments) operated at a flow rate of 15 ml h-'. Apparent
molecular weights were estimated using known molecular
weight proteins. Fractions rich in haemolytic activity were
concentrated by ultrafiltration, dialysed against a borate
buffer, pH 8.0, and applied to an epoxy-activated Sepharose
6B chelated column (1.6 x 6.5 cm) charged with ZnC12 as per
manufacturers' instructions (Pharmacia Fine Chemicals).
Following application of the sample the column was washed
with borate buffer. Bound proteins were sequentially eluted
with 25 mM sodium cacodylate buffer (pH 6.5) in 0.8 M
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NaCI, sodium acetate buffer pH 4.5, and EDTA, pH 4.0, as
described by Cawston and Murphy (1981). These purification
procedures were done at 4°C. Samples were immediately
neutralised to pH 7.0, dialysed against HEPES buffered NaCl
(150 mM), and tested for haemolytic activity. The zinc col-
umn fraction with the highest specific activity was then ap-
plied to a 50 x 5 mm Mono Q HR 5/5 strong anion exchange
column operated at a flow rate of 1 ml min-' on a Fast
Protein Liquid Chromatography apparatus (Pharmacia). Fol-
lowing application of the sample and return of the optical
density (280 nm) to the baseline value, a 42 ml gradient of
0-0.5 M NaCl in 10 mM HEPES followed by a steeper
gradient to 1 M NaCl was used to elute the bound proteins.
Active gel filtration fractions were also applied to a Mono P
chromatofocusing column (Pharmacia) equilibrated with
0.25 M bis-Tris, pH 7.1. Bound proteins were eluted with
Polybuffer 74, pH 4.0.
To determine whether THF is secreted by the cell or
released as a component of shed membrane vesicles, tumour
conditioned media were centrifuged at 100,000g for 1 h.
Haemolytic activity was assayed in the pellet and super-
natant.
To assess the potential haemolytic activity of residual cell-
bound bovine serum albumin which is released by cells into
serum-free media, the 2 day conditioned media of trans-
formed fibroblasts was chromatographed on a Blue Seph-
arose CL-6B (Pharmacia) column equilibrated in 20 mM
HEPES (pH 7.5) buffer containing 5 mM CaCl2 and 0.1M
NaCl (Travis et al., 1976). Following collection of the void
volume, a 1.5 M NaCl buffer was used to elute the crude
albumin peak. Fractions were pooled, dialysed and tested for
haemolytic activity.
SDS PAGE electrophoresis
A discontinuous system for polyacrylamide gel electro-
phoresis in sodium dodecyl sulphate was employed using the
gel buffer and sample preparation system of Laemmli (1970).
Gels were stained with Coomassie blue. Molecular weight
standards were run concurrently and approximate molecular
weights were determined by plotting the relative mobilities of
the known proteins.
RBC cytolysis assay
The tumour induced RBC cytolysis assay (TIRC) and inhi-
bitor assays were performed as previously described (Zucker
et al., 1985a; Wieman et al., 1986). Cytotoxicity was ex-
pressed as a release index (RI%):
((radioactivity in the supernate)/
(total radioactivity in the supernate and pellet)) x 100
The effect of inhibitors on RBC cytolysis were calculated
using the formula:
(1 -(Rldrug treated THF or cells-RIcontrol)/
(RIuntreated THF orcells-RIcontrol)) X 100
Treatment of THF with trypsin for 1 h at 37C was per-
formed to ascertain whether the haemolytic factor was
susceptible to protease digestion. Trypsin was then in-
activated with an excess of soybean trypsin inhibitor.
Protease assays
Collagenase and gelatinase assays were performed using
native or heat-denatured 3H-methyl collagen (2yg substrate
per assay) as previously described (Zucker et al., 1985b).
Immunologicalprocedures
Polyclonal antibodies to THF were produced in rabbits by a
total of six injections of 360jig of THF over a 5-month
period; two subcutaneous injections of emulsified THF in
complete Freund's adjuvant were followed by four intra-
venous injections. Rabbits were bled and IgG was isolated
from serum using a Protein A-Sepharose CL-4B column as
per manufacturer's instructions (Pharmacia).
In view ofpotential contamination of the THF preparation
with bovine serum albumin (BSA), the anti THF IgG was
passed through an Affi-Gel 10 column to which BSA had
been covalently coupled at pH 4.8 (BioRad, Richmond, CA,
USA). The unbound IgG pool was free of immunological
reactivity with BSA on Western blotting.
Immunoblotting was performed following transfer of pro-
teins from an SDS-PAGE gel to nitrocellulose paper. Protein
bands were probed using rabbit anti-THF IgG (diluted 1:100)
and goat antirabbit IgG labelled with horseradish peroxidase
as described by Spinucci et al. (1988). Immunoblotting for
murine tumour necrosis factor and for lymphocyte Perforin
was performed using specific rabbit polyclonal antibodies
(diluted 1:100).
Miscellaneous
Protein determinations were made by the method of Bohlen
et al. (1973) using bovine serum albumin standards.
Monoacylglycerol lipase, diacyglycerol lipase, lysophospho-
lipase, and phospholipase C activities were determined by the
method of Farooqui et al. (1984) using rac-l-S-decanoyl-l-
mercapto-2,3-propanediol, rac 1,2-S,0-didecanoyl-1-mercapto-
2, 3-propanediol, 2-hexadecanoylthio-1-ethyl-phosphocholine
and rac-1-S-phosphocholine-2,3-0-didecanoyl-1-mercapto-2,3-
propanediol, respectively.
Statistical analysis was done by Student's t test.
Results
Haemolytic activity ofintactfibroblasts
Incubation of non-transformed 3T3 fibroblasts with 59Fe-
labelled RBCs did not result in lysis of the target cells, but
in fact, led to a decrease in baseline RBC lysis (release
index = 5 ± 2%; buffer control RI = 9 + 1%) which appears
to be related to a protective effect of the adherent 3T3 cells
covering the surface of the dish. The protective effect of
non-transformed 3T3 cells was not evident in non-confluent
dishes. Harvey murine sarcoma viral oncogene transformed
mouse 3T3 cells extensively lysed the target RBCs during a 2
day incubation period (RI = 81 ± 3%). Tumour cell induced
haemolysis could be demonstrated in the presence or absence
of serum in the media. In contrast, 3T3 fibroblasts trans-
formed by T24 human bladder cancer DNA did not consis-
tently lyse co-cultured RBCs (RI = 5-20%).
Cell doubling times of 3T3 fibroblasts, viral transformed
fibroblasts, and T24 transformed fibroblasts were 23 ± 1 h,
23 + 1 h, and 22 ± 1 h respectively in dishes containing calf
serum.
Purification and characterisation oftumour haemolyticfactor
In contrast to the intact cells, haemolytic activity was more
readily purified from the conditioned medium of T24 trans-
formed fibroblasts than viral oncogene transformed fibro-
blasts.
Crude conditioned medium harvested from T24 bladder
transformed fibroblasts contained relatively low levels of
RBC lytic activity: 0.2%, 0.3%, 0.3% and 0.4% per mg
protein (results of four separate experiments). Following cen-
trifugation of conditioned medium at 100,000g for 1 h, the
total amount of haemolytic activity was recovered in the
supernatant; the resuspended pellet lacked activity. This
indicates that the haemolytic factor is soluble (sTHP) and is
not a component of shed vesicles.
The purification scheme that we previously reported for
soluble THF with T-24 transformed fibroblast conditioned
medium resulted in a 6-fold enrichment ofhaemolytic activity
compared to the ammonium sulphate precipitated material
(Wieman et al., 1986). This scheme has been modified in this
report to provide more than a 230-fold enrichment in30 S. ZUCKER et al.
haemolytic activity compared to the ammonium sulphate
precipitated. Following ammonium sulphate precipitation
(60-100% saturation), gel filtration on AcA 44 resulted in
elution of haemolytic factor with an apparent molecular
weight of 65-75 kDa (data not shown). Gelatinolytic activity,
which was more highly enriched in the 0-60% ammonium
sulphate precipitate, eluted in a fraction of lower molecular
weight (Table I). Minimal collagenolytic activity was detected
in any of the THF-enriched fractions. Zinc chelate column
chromatography resulted in further enrichment of THF with
elution of highest specific haemolytic activity with sodium
acetate buffer, pH4.5 (Figure 1). Other fractions also con-
tained haemolytic activity, but were less pure as visualised by
SDS PAGE. Anion exchange chromatography on Mono Q
resulted in binding of the haemolytic activity to the column
and elution at a NaCl concentration of approximately
150mM (Figure 2a). The enrichment in haemolytic activity
after anion exchange chromatography was approximately
3,800-fold compared to the starting conditioned media
(Table I). Following the chromatographic purification steps,
the total recovery of haemolytic activity exceeded that of the
starting conditioned media. Chromatofocusing of the active
fraction isolated from the gel filtration column resulted in the
elution of tumour haemolytic factor (THF) at a pH between
5 and 6.
The purification of THF from Ha-MuSV transformed
fibroblasts conditioned media resulted in a different
chromatographic pattern than observed with T24 haemolytic
factor. THF isolated from Ha-MuSV transformed cells had a
similar apparent molecular weight (74,000), but was less
tightly bound to the zinc chelate column and did not bind to
the Mono Q anion exchange column as noted with T24
haemolytic factor (Figures lb, 2b). Likewise, the specific
haemolytic activity of THF purified from Ha-Mu-SV trans-
formed cells was lower than with T24 transformed cells
(0.58% lysis tg-1 versus 1.15% lysis ig-' protein, respec-
tively).
In our previous report (Wieman et al., 1986), sTHF was
shown to be partially inhibited by EDTA, a metal chelator,
and totally inhibited by human serum. Broad spectrum
inhibitors of serine proteases and cysteine proteases had no
inhibitory effect on RBC lytic activity. In the current study,
no inhibition of THF was noted with soybean trypsin
inhibitor (24 JAM), pepstatin (0.5 JM), the aspartic protease
inhibitor, phosphoramidon, (1 JM), the specific metalollo-
protease inhibitor and tissue inhibitor of metalloproteases
(TIMP) (4 JLM). Treatment of purified sTHF with 25 and
1,000 ig ml-' of trypsin resulted in 29 and 62% inactivation
of sTHF, respectively.
Sodium dodecyl sulphate polyacrylamide gel electropho-
resis of sTHF from fibroblasts transformed by either human
cancer or viral Ha-ras oncogene showed sTHF to have an Mr
of 66,000 (Figure 3a). Silver staining of the gel or increasing
the protein content per sample did not reveal contaminating
protein bands on SDS-PAGE (data not shown).
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Figure 1 Zinc chelate column chromatography of the partially
purified tumour haemolytic factor. a represents the chromato-
gram from human bladder cancer T-24 transformed fibroblasts
and b represents the chromatogram from Ha-MuSV transformed
fibroblasts. The active haemolytic pools from the gel filtration
column were concentrated, dialysed against borate buffer, pH 8.0,
and applied to an epoxy-activated Sepharose 6B chelate column
charged with ZnC12. Following application of the sample and
washing with additional borate buffer, the bound proteins
(measured at OD280) were sequentially eluted in a stepwise man-
ner as indicated by the arrows with 25 mM sodium cacodylate
buffer (pH 6.5) in 0.8 M NaCl, then sodium acetate buffer (pH
4.5), and finally EDTA (pH 4.0). Fractions were immediately
neutralised to pH 7.0, dialysed against HEPES buffered saline,
and assayed without delay for haemolytic activity (expressed as
release index (hatched bars)). Differences in the elution of
haemolytic activity (THF) were noted between T24 and Ha-
MuSV proteins.
In view of the potential contamination of purified sTHF
by the cell bound bovine albumin in the original culture
medium, transformed fibroblast conditioned media was
chromatographed on a Blue Sepharose CL-6B (Pharmacia)
column. All ofthe cytolytic activity was recovered in the void
volume. The albumin peak (Mr 66,000), eluted with 1.5 M
Table I Purification of tumour haemolytic factor
Gelatinolytic
SHA SHA Total Total activity activity Gelatinolytic
Sample (% mg-') enrichment protein (units HAb (gAgmg-') enrichment
T-24 conditioned media 0.3±0.68 1 5968 1790 0.08±0.01 1.0
0-60% (NH4)2SO4 2.7±0.5 9 541 1461 0.62±0.09 8.1
60-100% (NH4)2SO4 4.9±1.6 16 359 1758 0.04±0.00 0.5
Ultragel AcA 44 125±10 417 59 7349 0.30±0.01 3.9
Zn-chelate Seph. 517±24 1873 29 14939 0.25±0.01 3.2
(acetate eluted)
Anion exchange 1155±167 3849 4.5 5080 0.18±0.03 2.3
(Mono Q)
aMean±standard error ofthe mean. bI unit haemoloytic activity (HA) = I% lysis ofS million RBC's.
Conditioned medium from T24 oncogene transformed fibroblasts was subjected to ammonium sulphate
precipitation followed by sequential chromatographic purification procedures on gel filtration, zinc-chelate
Sepharose, and anion exchange on Mono Q. The results were expressed as specific haemolytic activity
(SHA) = (release index % ofsample) - (release index % ofbuffer) . mgprotein, and gelatinolytic activity (ggelatindegraded permgprotein), aswell as theenrichment factor = (activityofsample/activity ofT-24
conditioned media).
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Figure 2 Anion exchange chromatography of partially purified
tumour haemolytic factor. a represents the chromatogram from
human bladder cancer T-24 transformed fibroblasts and b re-
presents the chromatogram from Ha-MuSV transformed fibro-
blasts. The active haemolytic fraction from the zinc chelated
column (Figure 1) were applied to a 50 x 5 mm Mono Q HR 5/5
strong anion exchange column. Protein separation was carried
out on a Fast Protein Liquid Chromatography apparatus from
Pharmacia operated at a flow rate of 1 ml min-'. Following
application of the sample and return of the optical density to
baseline (OD280), a 42 ml gradient of 0.5 M NaCl in 10 mM
HEPES, followed by a steeper gradient to I M NaCl was used to
elute bound proteins. The release index, as depicted by the
dashed line, shows that T24 haemolytic factor was eluted at
approximately 0.15 M NaCI whereas Ha-MuSV haemolytic factor
was eluted in the unbound fraction. The enclosed represents the
active haemolytic fractions that were pooled for further puri-
fication.
NaCI, was free of haemolytic activity (data not shown).
Soluble THF (34-61 tLg per sample) purified from T24 and
Ha-MuSV transformed fibroblast conditioned media did not
contain detectable amounts of monoacylglycerol lipase, dia-
cylglycerol lipase, lysophospholipase or phospholipase C.
Immunological testing of THF
Rabbit IgG anti-THF, rendered free of reactivity with BSA,
demonstrated a strong band of reactivity at M, = 77,000 with
THF on Western immunoblots (Figure 3b). THF did not
cross-react in Western immunoblots with antibodies to lym-
phocyte Perforin or with antibodies to tumour necrosis factor
(data not shown).
Discussion
In 1977, Zucker and Lysik reported that intact rat breast
carcinoma cells were able to lyse erythrocytes and normal
bone marrow erythroblasts during a 24 hour co-incubation
period. Tumour-induced erythroid cytolysis occurred at 37°C,
required direct contact between target and viable effector
cells, was independent of DNA synthesis, and was mediated
by integral plasma membrane proteins (DiStefano et al.,
1982). Since then, more than a dozen other spontaneous,
viral and chemically transformed cancer cell lines have been
shown to have the capacity to lyse erythrocytes (Lysik et al.,
b Mr
130 k
75
50
37
27
1 2 3
Figure 3 a, sodium dodecyl sulphate polyacrylamide gel (7.5%)
electrophoresis of tumour haemolytic factor (THF) purified from
Human T-24 cancer and viral ras oncogene transformed fibro-
blasts and stained with Coomassie Blue. THF was purified by
60- 100% ammonium sulphate precipation, gel filtration chroma-
tography, Zinc chelated column chromatography, and anion
exchange chromatography. Lane I shows T-24 conditioned
media. Lane 2 shows the 60-100% ammonium sulphate pre-
cipitate. Lane 3 shows T-24 partially purified THF isolated on a
Zinc chelate column. Lane 4 shows the T-24 THF isolated on an
anion exchange column. Lanes 5 and 6 show the purification of
THF from Ha-MuSV oncogene transformed fibroblasts after
Zinc chelate column and anion exchange column chromato-
graphy, respectively. Lane 7 shows the molecular weight marker
proteins (phosphorylase B, 92,500; bovine serum albumin, 66,200;
ovalbumin, 45,000; carbonic anhydrase, 31,000; soybean trypsin
inhibitor, 21,500; lysozyme, 14,000). b, immunoblotting of
tumour haemolytic factor purified from Ha-MuSV transformed
fibroblasts. After blocking of non-specific binding sites with 1%
bovine serum albumin, rabbit anti-THF immune IgG was
incubated with nitrocellulose strips for 2 h at room temperature.
Peroxidase reaction was visualised with the use of 4-chloro-1-
naphthol and H202 substrate. Lane 1 contains prestained
molecular weight standards; lane 2 contains THF purified from
Ha-MuSV transformed fibroblasts; lane 3 contains bovine serum
albumin.
1979; Zucker et al., 1985b; DiStefano, 1986). Non-trans-
formed cell lines lack haemolytic activity.
To understand better the haemolytic properties of cancer
cells, we have purified a soluble tumour haemolytic factor
(sTHF) from serum-free media produced by two different
Harvey ras oncogene transformed cell lines. Both cell lines
are highly malignant and kill virtually 100% of nude mice32 S. ZUCKER et al.
within 3 weeks of transplantation. An apparent paradox,
however, is noted in measuring the haemolytic activity of
intact transformed cell lines compared to their release of
sTHF in vitro. Intact NIH-3T3 fibroblasts transformed by
DNA from T-24 bladder cancer cells are not able to lyse
RBCs in vitro. Nonetheless, T-24 transformed cells release
large amounts of sTHP into 2-day conditioned media. One
explanation for the lack of haemolytic activity of intact T-24
transformed fibroblasts might be the long duration of pro-
pagation of this cell line in vitro (2 years) which in other
tumour cell lines has led to a disappearance of haemolytic
activity (Zucker et al., 1985a). In contrast, intact viral Ha-ras
transformed cells readily lyse RBCs in vitro, but release sTHP
of lower specific activity than T-24 transformed cells. A
plausible hypothesis is that the haemolysis induced by intact
cancer cells is mediated by a tumour membrane-bound
haemolytic factor rather than s-THF. We have recently been
able to extract a crude haemolytic factor from the mem-
branes of both viral and T-24 ras transformed cells. The
detergent extracted haemolytic factor differs from sTHF not
only in its membrane localisation, but also in its chemical
and heat stability and inhibition profile with pharmacological
agents (Zucker, unpublished data).
In this study, we described a greater than 3,000-fold puri-
fication of sTHF from 2 day conditioned media produced by
human T24 ras transformed fibroblasts and Ha-MuSV trans-
formed cells. Incubation of purified sTHF with 5 million
RBCs for 2 days resulted in the lysis ofapproximately 1% of
the cells per .tg protein (Table I).
THF is a protein of 66,000 Da (as demonstrated by SDS-
PAGE), and is susceptible to digestion by trypsin. Soluble
THF was identified on immunoblotting as a protein of ap-
proximately 77,000 Da. These small differences in molecular
weight determinations are probably technical in nature.
Purified THF is not a serine, cysteine or aspartic protease as
demonstrated by the absence of inhibition by appropriate
protease inhibitors. The metal chelator, EDTA, partially
inhibited THF activity indicating the metal dependence of
THF. However, sequential purification of THF did not lead
to enrichment of metal-dependent gelatinolytic or collagen-
olytic activities, thus reducing the likelihood that THF
is a member of the collagenase family of metalloprotease.
Furthermore, THF was not inhibited by the collagenase-
gelatinase inhibitor, tissue inhibitor ofmetalloproteases. THF
lacked mono and diacylglycerol lipase, lysophospholipase or
phospholipase C activity, thus ruling out this mechanism of
red cell membrane disruption.
The possibility of a relationship between sTHP and cyto-
kines produced by T lymphocytes and killer cells (Perforin)
and activated monocytes (tumour necrosis factor) was ex-
plored in this report. Perforin resembles sTHP in terms of its
molecular weight, heat instability, inactivation by metal
chelation or serum, and requirement for cell-cell contact for
activity, but differs in several important aspects (Henkart,
1985; Podack, 1986). Perforin is capable of lysing RBCs in
minutes, whereas THF requires a 2 day incubation. Perforin
is localised in lymphocyte granules, whereas THF is readily
released by tumour cells in vitro. Antibodies to Perforin did
not cross-react with sTHF on immunoblotting or dot blot-
ting. Of interest, Perforin has been isolated from a long-term
lymphocyte cell line that no longer has cytolytic capacity
(Henkart, 1985) which is analagous to our purification of
THF from T24 transformed fibroblasts that lack cytolytic
activity.
Antibodies to murine tumour necrosis factor (Beutler et
al., 1985) did not cross-react with sTHF. Tumour necrosis
factor also differs from sTHP in molecular weight and bio-
logical activity.
Having purified a protein with haemolytic capacity from
tumour cells, we are presented with new questions dealing
with the mechanism of action of this factor and the potential
role that sTHF may play in the processes of cancer invasion
or in the anaemia that accompanies disseminated cancer.
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